{"id":53858,"date":"2023-02-13T15:03:07","date_gmt":"2023-02-13T14:03:07","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/lytgobi-futibatinib-now-available-from-onco360-for-the-treatment-of-adult-patients-with-previously-treated-unresectable-locally-advanced-or-metastatic-intrahepatic-cholangiocarcinoma-harbori\/"},"modified":"2023-02-13T15:03:07","modified_gmt":"2023-02-13T14:03:07","slug":"lytgobi-futibatinib-now-available-from-onco360-for-the-treatment-of-adult-patients-with-previously-treated-unresectable-locally-advanced-or-metastatic-intrahepatic-cholangiocarcinoma-harbori","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/lytgobi-futibatinib-now-available-from-onco360-for-the-treatment-of-adult-patients-with-previously-treated-unresectable-locally-advanced-or-metastatic-intrahepatic-cholangiocarcinoma-harbori\/","title":{"rendered":"Lytgobi\u00ae (futibatinib) Now Available from Onco360 for the Treatment of Adult Patients with Previously Treated, Unresectable, Locally Advanced or Metastatic Intrahepatic Cholangiocarcinoma Harboring FGFR2 Gene Fusions or Other Rearrangements"},"content":{"rendered":"
\n

LOUISVILLE, Ky.–(BUSINESS WIRE)–Onco360\u00ae<\/sup>, the nation\u2019s leading independent Specialty Pharmacy, has been selected by Taiho Oncology to be a specialty pharmacy partner for Lytgobi\u00ae (futibatinib), which is a kinase inhibitor indicated for the treatment of adult patients with previously treated, unresectable, locally advanced or metastatic intrahepatic cholangiocarcinoma harboring fibroblast growth factor receptor 2 (FGFR2) gene fusions or other rearranagements. This indication is approved under accelerated approval based on overall response rate and duration of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial.\n<\/p>\n

<\/a><\/p>\n

\n\u201cOnco360 is honored to partner with Taiho Oncology and become a specialty pharmacy provider for Lytgobi patients,\u201d said Benito Fernandez, Chief Commercial Officer, Onco360. \u201cWe are committed to supporting the highly specialized needs of patients battling treatment-experienced, FGFR2-mutant, advanced cholangiocarcinoma patients across the United States.\u201d\n<\/p>\n

\nAccording to the American Cancer Society (ACS), it is estimated that 8,000 patients will be diagnosed with cholangiocarcinoma annually. The five-year overall survival (OS) for cholangiocarcinoma, regardless of stage, is only 9%. With regard to cholangiocarcinoma patients with distant metastatic disease, the five-year OS is only 2%.1<\/sup> Approximately 20% of cholangiocarcinoma cases are considered intrahepatic in terms of tumor location.2<\/sup> 10-16% of intrahepatic cholangiocarcinoma cases have FGFR2 mutations.3<\/sup>\n<\/p>\n

\nLytgobi is developed and commercialized by Taiho Oncology. The FDA approval of Lytgobi comes as a result of the Phase I\/II, open-label, single-arm TAS-120-101 (NCT02052778) clinical trial which evaluated the use of Lytgobi in previously treated, unresectable, locally advanced, or metastatic intrahepatic cholangiocarcinoma patients. The TAS-120-101 demonstrated that Lytgobi administration resulted in a 42% overall response rate (ORR) in 103 study participants.4<\/sup>\n<\/p>\n

\nAbout Onco360 Oncology Pharmacy:<\/b>\n<\/p>\n

\nOnco360 is the nation\u2019s largest independent Oncology Pharmacy and clinical support services company. Onco360 was founded in 2003 to bring together the stakeholders involved in the cancer treatment process and serve the specialized needs of oncologists, patients, hospitals, cancer centers of excellence, manufacturers, health plans, and payers. It dispenses nationally through its network of URAC-, and ACHC-accredited Oncology Pharmacies. Onco360 is headquartered in Louisville, Kentucky, and is a flagship specialty pharmacy brand of PharMerica Corporation, a leading institutional pharmacy, specialty infusion, and hospital services company servicing healthcare facilities in the United States. For more information about Onco360, please visit Onco360.com<\/a>.\n<\/p>\n

\nReferences:\n<\/p>\n

    \n
  1. \nAll statistics from https:\/\/www.cancer.org\/cancer\/bile-duct-cancer\/about\/key-statistics.html#:~:text=Bile%20duct%20cancer%20(cholangiocarcinoma)%20is,diagnosed%20with%20it%20each%20year<\/a>. accessed on 10\/24\/2022\n<\/li>\n
  2. \nValle JW et al. Biliary Tract Cancer. Lancet. 2021;397:428-444\n<\/li>\n
  3. \nFDA Approves Taiho’s LYTGOBI\u00ae (futibatinib) Tablets for Previously Treated, Unresectable, Locally Advanced or Metastatic Intrahepatic Cholangiocarcinoma (prnewswire.com)<\/a>. accessed on 10\/24\/2022\n<\/li>\n
  4. \nLYTGOBI_Prescribing_Information.pdf (amazonaws.com)<\/a>. accessed on 10\/24\/2022.\n<\/li>\n<\/ol>\n

    \n\u00a0\n<\/p>\n

    Contacts<\/b> <\/p>\n

    \nBenito Fernandez, Chief Commercial Officer
    \n
    benito.fernandez@onco360.com<\/a>
    516-640-1332\n<\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"

    LOUISVILLE, Ky.–(BUSINESS WIRE)–Onco360\u00ae, the nation\u2019s leading independent Specialty Pharmacy, has been selected by Taiho Oncology to be a specialty pharmacy partner for Lytgobi\u00ae (futibatinib), which is a kinase inhibitor indicated for the treatment of adult patients with previously treated, unresectable, locally advanced or metastatic intrahepatic cholangiocarcinoma harboring fibroblast growth factor receptor 2 (FGFR2) gene fusions … [Read more…]<\/a><\/span><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[],"class_list":["entry","post","publish","author-business","post-53858","format-standard","category-industry"],"yoast_head":"\nLytgobi\u00ae (futibatinib) Now Available from Onco360 for the Treatment of Adult Patients with Previously Treated, Unresectable, Locally Advanced or Metastatic Intrahepatic Cholangiocarcinoma Harboring FGFR2 Gene Fusions or Other Rearrangements - Pharma Trend<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pharma-trend.com\/en\/lytgobi-futibatinib-now-available-from-onco360-for-the-treatment-of-adult-patients-with-previously-treated-unresectable-locally-advanced-or-metastatic-intrahepatic-cholangiocarcinoma-harbori\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Lytgobi\u00ae (futibatinib) Now Available from Onco360 for the Treatment of Adult Patients with Previously Treated, Unresectable, Locally Advanced or Metastatic Intrahepatic Cholangiocarcinoma Harboring FGFR2 Gene Fusions or Other Rearrangements - Pharma Trend\" \/>\n<meta property=\"og:description\" content=\"LOUISVILLE, Ky.–(BUSINESS WIRE)–Onco360\u00ae, the nation\u2019s leading independent Specialty Pharmacy, has been selected by Taiho Oncology to be a specialty pharmacy partner for Lytgobi\u00ae (futibatinib), which is a kinase inhibitor indicated for the treatment of adult patients with previously treated, unresectable, locally advanced or metastatic intrahepatic cholangiocarcinoma harboring fibroblast growth factor receptor 2 (FGFR2) gene fusions ... [Read more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pharma-trend.com\/en\/lytgobi-futibatinib-now-available-from-onco360-for-the-treatment-of-adult-patients-with-previously-treated-unresectable-locally-advanced-or-metastatic-intrahepatic-cholangiocarcinoma-harbori\/\" \/>\n<meta property=\"og:site_name\" content=\"Pharma Trend\" \/>\n<meta property=\"article:published_time\" content=\"2023-02-13T14:03:07+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mms.businesswire.com\/media\/20230213005334\/en\/1711712\/21\/image001.jpg\" \/>\n<meta name=\"author\" content=\"Business Wire\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Business Wire\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/lytgobi-futibatinib-now-available-from-onco360-for-the-treatment-of-adult-patients-with-previously-treated-unresectable-locally-advanced-or-metastatic-intrahepatic-cholangiocarcinoma-harbori\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/lytgobi-futibatinib-now-available-from-onco360-for-the-treatment-of-adult-patients-with-previously-treated-unresectable-locally-advanced-or-metastatic-intrahepatic-cholangiocarcinoma-harbori\\\/\"},\"author\":{\"name\":\"Business Wire\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\"},\"headline\":\"Lytgobi\u00ae (futibatinib) Now Available from Onco360 for the Treatment of Adult Patients with Previously Treated, Unresectable, Locally Advanced or Metastatic Intrahepatic Cholangiocarcinoma Harboring FGFR2 Gene Fusions or Other Rearrangements\",\"datePublished\":\"2023-02-13T14:03:07+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/lytgobi-futibatinib-now-available-from-onco360-for-the-treatment-of-adult-patients-with-previously-treated-unresectable-locally-advanced-or-metastatic-intrahepatic-cholangiocarcinoma-harbori\\\/\"},\"wordCount\":479,\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/lytgobi-futibatinib-now-available-from-onco360-for-the-treatment-of-adult-patients-with-previously-treated-unresectable-locally-advanced-or-metastatic-intrahepatic-cholangiocarcinoma-harbori\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20230213005334\\\/en\\\/1711712\\\/21\\\/image001.jpg\",\"articleSection\":[\"Industry\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/lytgobi-futibatinib-now-available-from-onco360-for-the-treatment-of-adult-patients-with-previously-treated-unresectable-locally-advanced-or-metastatic-intrahepatic-cholangiocarcinoma-harbori\\\/\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/lytgobi-futibatinib-now-available-from-onco360-for-the-treatment-of-adult-patients-with-previously-treated-unresectable-locally-advanced-or-metastatic-intrahepatic-cholangiocarcinoma-harbori\\\/\",\"name\":\"Lytgobi\u00ae (futibatinib) Now Available from Onco360 for the Treatment of Adult Patients with Previously Treated, Unresectable, Locally Advanced or Metastatic Intrahepatic Cholangiocarcinoma Harboring FGFR2 Gene Fusions or Other Rearrangements - Pharma Trend\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/lytgobi-futibatinib-now-available-from-onco360-for-the-treatment-of-adult-patients-with-previously-treated-unresectable-locally-advanced-or-metastatic-intrahepatic-cholangiocarcinoma-harbori\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/lytgobi-futibatinib-now-available-from-onco360-for-the-treatment-of-adult-patients-with-previously-treated-unresectable-locally-advanced-or-metastatic-intrahepatic-cholangiocarcinoma-harbori\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20230213005334\\\/en\\\/1711712\\\/21\\\/image001.jpg\",\"datePublished\":\"2023-02-13T14:03:07+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/lytgobi-futibatinib-now-available-from-onco360-for-the-treatment-of-adult-patients-with-previously-treated-unresectable-locally-advanced-or-metastatic-intrahepatic-cholangiocarcinoma-harbori\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/pharma-trend.com\\\/en\\\/lytgobi-futibatinib-now-available-from-onco360-for-the-treatment-of-adult-patients-with-previously-treated-unresectable-locally-advanced-or-metastatic-intrahepatic-cholangiocarcinoma-harbori\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/lytgobi-futibatinib-now-available-from-onco360-for-the-treatment-of-adult-patients-with-previously-treated-unresectable-locally-advanced-or-metastatic-intrahepatic-cholangiocarcinoma-harbori\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20230213005334\\\/en\\\/1711712\\\/21\\\/image001.jpg\",\"contentUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20230213005334\\\/en\\\/1711712\\\/21\\\/image001.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/lytgobi-futibatinib-now-available-from-onco360-for-the-treatment-of-adult-patients-with-previously-treated-unresectable-locally-advanced-or-metastatic-intrahepatic-cholangiocarcinoma-harbori\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Lytgobi\u00ae (futibatinib) Now Available from Onco360 for the Treatment of Adult Patients with Previously Treated, Unresectable, Locally Advanced or Metastatic Intrahepatic Cholangiocarcinoma Harboring FGFR2 Gene Fusions or Other Rearrangements\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"name\":\"Pharma Trend\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\",\"name\":\"Pharma Trend\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Pharma Trend\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\",\"name\":\"Business Wire\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Lytgobi\u00ae (futibatinib) Now Available from Onco360 for the Treatment of Adult Patients with Previously Treated, Unresectable, Locally Advanced or Metastatic Intrahepatic Cholangiocarcinoma Harboring FGFR2 Gene Fusions or Other Rearrangements - Pharma Trend","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pharma-trend.com\/en\/lytgobi-futibatinib-now-available-from-onco360-for-the-treatment-of-adult-patients-with-previously-treated-unresectable-locally-advanced-or-metastatic-intrahepatic-cholangiocarcinoma-harbori\/","og_locale":"en_US","og_type":"article","og_title":"Lytgobi\u00ae (futibatinib) Now Available from Onco360 for the Treatment of Adult Patients with Previously Treated, Unresectable, Locally Advanced or Metastatic Intrahepatic Cholangiocarcinoma Harboring FGFR2 Gene Fusions or Other Rearrangements - Pharma Trend","og_description":"LOUISVILLE, Ky.–(BUSINESS WIRE)–Onco360\u00ae, the nation\u2019s leading independent Specialty Pharmacy, has been selected by Taiho Oncology to be a specialty pharmacy partner for Lytgobi\u00ae (futibatinib), which is a kinase inhibitor indicated for the treatment of adult patients with previously treated, unresectable, locally advanced or metastatic intrahepatic cholangiocarcinoma harboring fibroblast growth factor receptor 2 (FGFR2) gene fusions ... [Read more...]","og_url":"https:\/\/pharma-trend.com\/en\/lytgobi-futibatinib-now-available-from-onco360-for-the-treatment-of-adult-patients-with-previously-treated-unresectable-locally-advanced-or-metastatic-intrahepatic-cholangiocarcinoma-harbori\/","og_site_name":"Pharma Trend","article_published_time":"2023-02-13T14:03:07+00:00","og_image":[{"url":"https:\/\/mms.businesswire.com\/media\/20230213005334\/en\/1711712\/21\/image001.jpg","type":"","width":"","height":""}],"author":"Business Wire","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Business Wire","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pharma-trend.com\/en\/lytgobi-futibatinib-now-available-from-onco360-for-the-treatment-of-adult-patients-with-previously-treated-unresectable-locally-advanced-or-metastatic-intrahepatic-cholangiocarcinoma-harbori\/#article","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/lytgobi-futibatinib-now-available-from-onco360-for-the-treatment-of-adult-patients-with-previously-treated-unresectable-locally-advanced-or-metastatic-intrahepatic-cholangiocarcinoma-harbori\/"},"author":{"name":"Business Wire","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24"},"headline":"Lytgobi\u00ae (futibatinib) Now Available from Onco360 for the Treatment of Adult Patients with Previously Treated, Unresectable, Locally Advanced or Metastatic Intrahepatic Cholangiocarcinoma Harboring FGFR2 Gene Fusions or Other Rearrangements","datePublished":"2023-02-13T14:03:07+00:00","mainEntityOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/lytgobi-futibatinib-now-available-from-onco360-for-the-treatment-of-adult-patients-with-previously-treated-unresectable-locally-advanced-or-metastatic-intrahepatic-cholangiocarcinoma-harbori\/"},"wordCount":479,"publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/lytgobi-futibatinib-now-available-from-onco360-for-the-treatment-of-adult-patients-with-previously-treated-unresectable-locally-advanced-or-metastatic-intrahepatic-cholangiocarcinoma-harbori\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20230213005334\/en\/1711712\/21\/image001.jpg","articleSection":["Industry"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/pharma-trend.com\/en\/lytgobi-futibatinib-now-available-from-onco360-for-the-treatment-of-adult-patients-with-previously-treated-unresectable-locally-advanced-or-metastatic-intrahepatic-cholangiocarcinoma-harbori\/","url":"https:\/\/pharma-trend.com\/en\/lytgobi-futibatinib-now-available-from-onco360-for-the-treatment-of-adult-patients-with-previously-treated-unresectable-locally-advanced-or-metastatic-intrahepatic-cholangiocarcinoma-harbori\/","name":"Lytgobi\u00ae (futibatinib) Now Available from Onco360 for the Treatment of Adult Patients with Previously Treated, Unresectable, Locally Advanced or Metastatic Intrahepatic Cholangiocarcinoma Harboring FGFR2 Gene Fusions or Other Rearrangements - Pharma Trend","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/lytgobi-futibatinib-now-available-from-onco360-for-the-treatment-of-adult-patients-with-previously-treated-unresectable-locally-advanced-or-metastatic-intrahepatic-cholangiocarcinoma-harbori\/#primaryimage"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/lytgobi-futibatinib-now-available-from-onco360-for-the-treatment-of-adult-patients-with-previously-treated-unresectable-locally-advanced-or-metastatic-intrahepatic-cholangiocarcinoma-harbori\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20230213005334\/en\/1711712\/21\/image001.jpg","datePublished":"2023-02-13T14:03:07+00:00","breadcrumb":{"@id":"https:\/\/pharma-trend.com\/en\/lytgobi-futibatinib-now-available-from-onco360-for-the-treatment-of-adult-patients-with-previously-treated-unresectable-locally-advanced-or-metastatic-intrahepatic-cholangiocarcinoma-harbori\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pharma-trend.com\/en\/lytgobi-futibatinib-now-available-from-onco360-for-the-treatment-of-adult-patients-with-previously-treated-unresectable-locally-advanced-or-metastatic-intrahepatic-cholangiocarcinoma-harbori\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/lytgobi-futibatinib-now-available-from-onco360-for-the-treatment-of-adult-patients-with-previously-treated-unresectable-locally-advanced-or-metastatic-intrahepatic-cholangiocarcinoma-harbori\/#primaryimage","url":"https:\/\/mms.businesswire.com\/media\/20230213005334\/en\/1711712\/21\/image001.jpg","contentUrl":"https:\/\/mms.businesswire.com\/media\/20230213005334\/en\/1711712\/21\/image001.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/pharma-trend.com\/en\/lytgobi-futibatinib-now-available-from-onco360-for-the-treatment-of-adult-patients-with-previously-treated-unresectable-locally-advanced-or-metastatic-intrahepatic-cholangiocarcinoma-harbori\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/pharma-trend.com\/en\/"},{"@type":"ListItem","position":2,"name":"Lytgobi\u00ae (futibatinib) Now Available from Onco360 for the Treatment of Adult Patients with Previously Treated, Unresectable, Locally Advanced or Metastatic Intrahepatic Cholangiocarcinoma Harboring FGFR2 Gene Fusions or Other Rearrangements"}]},{"@type":"WebSite","@id":"https:\/\/pharma-trend.com\/en\/#website","url":"https:\/\/pharma-trend.com\/en\/","name":"Pharma Trend","description":"","publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pharma-trend.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/pharma-trend.com\/en\/#organization","name":"Pharma Trend","url":"https:\/\/pharma-trend.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Pharma Trend"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24","name":"Business Wire"}]}},"_links":{"self":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/53858","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/comments?post=53858"}],"version-history":[{"count":0,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/53858\/revisions"}],"wp:attachment":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/media?parent=53858"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/categories?post=53858"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/tags?post=53858"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}